Vaxcyte Q1 net loss widensas  costs rise

Vaxcyte

06/05/2026 21:25

Overview

US vaccine developer's Q1 net loss widened and missed analyst expectations

Operating expenses rose, driven by higher R&D and manufacturing costs for vaccine programs

Company ended Q1 with $2.7 bln in cash after February equity offering

Outlook

Vaxcyte expects OPUS-1 Phase 3 topline data in Q4 2026

Company expects OPUS-2 and OPUS-3 Phase 3 results in first half of 2027

Vaxcyte plans to initiate VAX-A1 Phase 1 adult study in mid-2026

Result Drivers

R&D AND MANUFACTURING COSTS - Co said higher research and development and product manufacturing costs for PCV programs drove increased operating expenses

Company press release: ID:nGNX8HShx2

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
Miss
-$320.62 mln
-$256.39 mln (5 Analysts)
Q1 Operating Expenses
$345.85 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Vaxcyte Inc is $110.00, about 97.7% above its May 5 closing price of $55.64

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)